5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol,
NB001,
686301-48-4,
5-{[2-(6-AMINO-9H-PURIN-9-YL)ETHYL]AMINO}-1-PENTANOL,
5-((2-(6-Amino-9H-purin-9-yl)ethyl)amino)pentan-1-ol,
NB001,
UNII-J89QT81NBQ,
HTS 09836,
NB-001,
5-[2-(6-aminopurin-9-yl)ethylamino]pentan-1-ol,
J89QT81NBQ,
5-{[2-(6-amino-9H-purin-9-yl)ethyl]amino}pentan-1-ol,
5-[[2-(6-Amino-9H-purin-9-yl)ethyl]amino]-1-pentanol; HTS 09836,
5-[[2-(6-amino-9h-purin-9-yl)ethyl]amino]-1-pentanol,
HTS-09836,
AC1MDQ1H,
AC1Q52Y2,
SCHEMBL13697544,
CTK5C8287,
DTXSID30384648,
1-Pentanol, 5-((2-(6-amino-9H-purin-9-yl)ethyl)amino)-,
ZINC4334664,
MFCD03086724,
NB 001,
AKOS027320708,
ACN-051259,
API0025209,
DB12716,
TRA0075541,
NCGC00485185-01,
NB001, >=98% (HPLC),
RT-010436,
FT-0662044,
NanoHPX,
D02UOZ,
CID2815031,
Herpes labialis therapy (NanoStat topical formulation), NanoBio,
Herpes simplex virus type 1 (HSV-1) therapy (NanoStat topical formulation), NanoBio,
100-36-7,